SCHEMBL530285

SCHEMBL530285

Cc1c(C(N)=O)cccc1-c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.69
PDCD1 Q15116 3/20 0.50
CD274 Q9NZQ7 3/20 0.50
HNF4A P41235 1/20 0.50
MYC P01106 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
BRD4 O60885 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
PARP1 P09874 1/20 0.45
IKBKB O14920 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30034930 1.00 BCAT2 (0.69) BCAT2PDCD1CD274HNF4AMYC
SCHEMBL6307908 0.93 BCAT2 (0.65) BCAT2PDCD1CD274HNF4AMYC
Trifluoroacetic Acid SCHEMBL1785126 0.91 BCAT2 (0.57) BCAT2PDCD1CD274HNF4AMYC
SCHEMBL30471810 0.86 BCAT2 (0.52) BCAT2MYCBRD4KEAP1NFE2L2
SCHEMBL29941849 0.86 MKNK1 (0.55) BCAT2PDCD1CD274KEAP1NFE2L2
SCHEMBL7311563 0.85 BCAT2 (0.58) BCAT2PDCD1CD274BRD4NPC1
SCHEMBL3898825 0.85 BCAT2 (0.58) BCAT2PDCD1CD274MEN1KMT2A
SCHEMBL121422 0.85 HNF4A (0.63) BCAT2PDCD1CD274HNF4AMYC
SCHEMBL17803632 0.84 SLC6A4 (0.51) BCAT2MEN1KMT2AKEAP1NFE2L2
SCHEMBL13065950 0.83 PDCD1 (0.52) BCAT2PDCD1CD274HNF4AMYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108883122-A C-glycoside compounds useful for the treatment of diseases 菲姆布里昂医疗公司 2018-11-23 CN claimed
WO-2012014127-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-02-02 WO claimed
CN-101448792-A Compounds that potentiate AMPA receptors and their use in medicine GLAXO GROUP LTD (GB) 2009-06-03 CN claimed
CN-116041277-A Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-05-02 CN disclosed
US-10736829-B2 Use of certain hydroxybenzoic acid amides for masking unpleasant taste impressions SYMRISE AG (DE) 2020-08-11 US disclosed
CN-105164142-B Mannose Derivatives for the Treatment of Bacterial Infections 沃泰克斯药物股份有限公司 2019-03-08 CN disclosed
CN-108883122-A C-glycoside compounds useful for the treatment of diseases 菲姆布里昂医疗公司 2018-11-23 CN disclosed
US-20180311132-A1 USE OF CERTAIN HYDROXYBENZOIC ACID AMIDES FOR MASKING UNPLEASANT TASTE IMPRESSIONS SYMRISE AG (DE) 2018-11-01 US disclosed
CN-104804048-B N substituted benzyl amino phosphine clamp ring ruthenium diphosphine compounds and its preparation method and application 洛阳师范学院 2017-09-22 CN disclosed
US-9458110-B2 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-04 US disclosed
US-20160016910-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS BRISTOL-MEYERS SQUIBB COMPANY (US) 2016-01-21 US disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed
CN-1284957-A Imidazonaphthyridines and their use in inducing cytokine biosynthesis MINNESOTA MINING & MFG (US) 2001-02-21 CN disclosed
US-5889001-A TREATING CONDITIONS WHERE DECREASED VASOPRESSIN LEVELS ARE DESIRED AND DISEASES WITH EXCESS RENAL WATER REABSORPTION AMERICAN CYANAMID COMPANY (US) 1999-03-30 US disclosed
US-5854237-A Tricyclic diazepine vasopressin antagonists and oxytocin antagonists AMERICAN CYANAMID COMPANY (US) 1998-12-29 US disclosed
US-5843944-A Tricyclic diazepine vasopressin antagonists and oxytocin antagonists AMERICAN CYANAMID COMPANY (US) 1998-12-01 US disclosed
US-5736540-A CONGESTIVE HEART FAILURE AMERICAN CYANAMID COMPANY (US) 1998-04-07 US disclosed
US-5733905-A CONGESTIVE HEART FAILURE; KIDNEY DISORDERS AMERICAN CYANAMID COMPANY (US) 1998-03-31 US disclosed
CN-1166832-A Substituted biphenyl oxazolines BAYER AG (DE) 1997-12-03 CN disclosed
WO-1996022295-A9 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10736829-B2 Use of certain hydroxybenzoic acid amides for masking unpleasant taste impressions FAM222B, FAM83B, CDY1; CDY1B BCAT2 54/4885PDCD1 2090/4885CD274 2187/4885
US-20180311132-A1 USE OF CERTAIN HYDROXYBENZOIC ACID AMIDES FOR MASKING UNPLEASANT TASTE IMPRESSIONS FAM222B, FAM83B, CDY1; CDY1B BCAT2 54/4885PDCD1 2090/4885CD274 2187/4885
US-20160016910-A1 PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS ROCK1, ROCK2, MYLK BCAT2 3341/4885PDCD1 495/4885CD274 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.